Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2)

• Glavni autori: Paolo Gisondi (Autor), Alice B. Gottlieb (Autor), Boni Elewski (Autor), Matthias Augustin (Autor), Sandy McBride (Autor), Tsen-Fang Tsai (Autor), Christine de la Loge (Autor), Frederik Fierens (Autor), José M. López Pinto (Autor), Nicola Tilt (Autor), Mark Lebwohl (Autor)
• Format: Knjiga
• Izdano: Adis, Springer Healthcare, 2022-12-01T00:00:00Z.
• Teme: article
• Online pristup: Connect to this object online.

Abstract Introduction Certolizumab pegol (CZP) is an Fc-free, PEGylated, anti-tumour necrosis factor biologic. Safety and efficacy data for CZP over 3 years have been previously reported. We report 3-year quality of life (QoL) outcomes for patients treated with CZP, pooled from two phase 3 trials. M...